| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 46 | 2026 | 372 | 17.190 |
Why?
|
| Neoplasm, Residual | 13 | 2025 | 206 | 4.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2026 | 977 | 3.490 |
Why?
|
| Dexamethasone | 12 | 2026 | 318 | 2.650 |
Why?
|
| Oligopeptides | 10 | 2026 | 205 | 2.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2026 | 2661 | 2.140 |
Why?
|
| Maintenance Chemotherapy | 4 | 2025 | 96 | 1.490 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2026 | 335 | 1.450 |
Why?
|
| Transplantation, Autologous | 11 | 2026 | 397 | 1.380 |
Why?
|
| Antibodies, Monoclonal | 4 | 2025 | 1419 | 1.340 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 94 | 1.330 |
Why?
|
| Antineoplastic Agents | 4 | 2026 | 2381 | 1.120 |
Why?
|
| Mass Spectrometry | 2 | 2025 | 189 | 1.080 |
Why?
|
| Myeloma Proteins | 2 | 2025 | 36 | 1.070 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 383 | 1.010 |
Why?
|
| Humans | 65 | 2026 | 98363 | 0.980 |
Why?
|
| Paraproteinemias | 2 | 2025 | 19 | 0.940 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 51 | 0.940 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2024 | 11 | 0.920 |
Why?
|
| Geriatric Assessment | 4 | 2024 | 193 | 0.920 |
Why?
|
| Hematology | 1 | 2026 | 37 | 0.910 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 10 | 0.900 |
Why?
|
| Premedication | 1 | 2024 | 57 | 0.840 |
Why?
|
| Ambulatory Care | 1 | 2026 | 202 | 0.830 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2021 | 2 | 0.700 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 3 | 0.700 |
Why?
|
| Aged | 23 | 2026 | 21844 | 0.700 |
Why?
|
| Practice Guidelines as Topic | 3 | 2026 | 1116 | 0.690 |
Why?
|
| Middle Aged | 24 | 2026 | 29532 | 0.670 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 305 | 0.650 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 21 | 0.640 |
Why?
|
| Amyloidosis | 1 | 2022 | 136 | 0.620 |
Why?
|
| Cancer Survivors | 1 | 2021 | 108 | 0.600 |
Why?
|
| Daunorubicin | 1 | 2019 | 77 | 0.600 |
Why?
|
| Disease Management | 3 | 2026 | 377 | 0.590 |
Why?
|
| T-Lymphocytes | 6 | 2026 | 1334 | 0.580 |
Why?
|
| Cytarabine | 1 | 2019 | 218 | 0.570 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 137 | 0.570 |
Why?
|
| Bacterial Infections | 1 | 2020 | 184 | 0.570 |
Why?
|
| Male | 24 | 2026 | 47257 | 0.550 |
Why?
|
| Remission Induction | 1 | 2019 | 764 | 0.520 |
Why?
|
| B-Cell Maturation Antigen | 3 | 2026 | 21 | 0.510 |
Why?
|
| Female | 24 | 2026 | 51756 | 0.510 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2017 | 1 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2019 | 418 | 0.500 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2017 | 10 | 0.500 |
Why?
|
| Adult | 15 | 2026 | 29587 | 0.490 |
Why?
|
| Patient Care Team | 1 | 2019 | 318 | 0.490 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 358 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 850 | 0.480 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 8 | 0.450 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 195 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 602 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 444 | 0.440 |
Why?
|
| Aged, 80 and over | 7 | 2026 | 7418 | 0.440 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 686 | 0.430 |
Why?
|
| Precision Medicine | 1 | 2019 | 502 | 0.420 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2025 | 31 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 663 | 0.420 |
Why?
|
| Treatment Outcome | 9 | 2026 | 9770 | 0.400 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2025 | 83 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 907 | 0.380 |
Why?
|
| Physicians | 1 | 2020 | 685 | 0.380 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2026 | 116 | 0.370 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 264 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2026 | 423 | 0.340 |
Why?
|
| Flow Cytometry | 2 | 2024 | 722 | 0.310 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 3032 | 0.310 |
Why?
|
| Prognosis | 4 | 2026 | 4126 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 578 | 0.270 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 923 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1178 | 0.260 |
Why?
|
| 5-Methylcytosine | 2 | 2026 | 134 | 0.260 |
Why?
|
| Thalidomide | 2 | 2024 | 57 | 0.250 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2025 | 2 | 0.220 |
Why?
|
| Outpatients | 1 | 2026 | 106 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2026 | 104 | 0.210 |
Why?
|
| Quality of Life | 2 | 2024 | 1899 | 0.210 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 141 | 0.210 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2471 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 1195 | 0.200 |
Why?
|
| Withholding Treatment | 1 | 2024 | 130 | 0.200 |
Why?
|
| CD3 Complex | 1 | 2023 | 137 | 0.190 |
Why?
|
| Hydrazines | 1 | 2023 | 36 | 0.190 |
Why?
|
| Hypercalcemia | 1 | 2023 | 60 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2024 | 110 | 0.190 |
Why?
|
| Imides | 1 | 2022 | 27 | 0.190 |
Why?
|
| Consensus | 1 | 2024 | 309 | 0.180 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.180 |
Why?
|
| Bortezomib | 1 | 2022 | 83 | 0.180 |
Why?
|
| Triazoles | 1 | 2023 | 118 | 0.180 |
Why?
|
| Melphalan | 1 | 2022 | 98 | 0.180 |
Why?
|
| Bone Marrow | 1 | 2024 | 421 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 284 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2025 | 826 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 533 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 196 | 0.170 |
Why?
|
| Bone Marrow Examination | 1 | 2020 | 40 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 67 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 547 | 0.150 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 25 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 1775 | 0.150 |
Why?
|
| Asparaginase | 1 | 2019 | 38 | 0.150 |
Why?
|
| Philadelphia Chromosome | 1 | 2019 | 48 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2020 | 282 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 62 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 108 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 336 | 0.150 |
Why?
|
| Reference Standards | 1 | 2019 | 147 | 0.150 |
Why?
|
| Standard of Care | 1 | 2019 | 71 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 353 | 0.140 |
Why?
|
| Allografts | 1 | 2019 | 220 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2020 | 352 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 383 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 1027 | 0.130 |
Why?
|
| Palliative Care | 1 | 2019 | 290 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 209 | 0.130 |
Why?
|
| Sex Factors | 1 | 2020 | 1142 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 970 | 0.120 |
Why?
|
| Leukocyte Count | 1 | 2017 | 215 | 0.120 |
Why?
|
| Neoplasms | 2 | 2023 | 3348 | 0.120 |
Why?
|
| Rituximab | 1 | 2017 | 136 | 0.120 |
Why?
|
| Time Factors | 3 | 2020 | 5576 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 1102 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2026 | 4818 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1945 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 150 | 0.110 |
Why?
|
| Patient Selection | 1 | 2019 | 722 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2023 | 11039 | 0.110 |
Why?
|
| Body Weight | 1 | 2017 | 456 | 0.110 |
Why?
|
| Splanchnic Circulation | 1 | 2015 | 14 | 0.110 |
Why?
|
| Disease Progression | 1 | 2020 | 1615 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 346 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2017 | 461 | 0.110 |
Why?
|
| Serial Publications | 1 | 2014 | 2 | 0.100 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 18 | 0.100 |
Why?
|
| United States | 2 | 2026 | 8258 | 0.100 |
Why?
|
| Science | 1 | 2014 | 39 | 0.100 |
Why?
|
| Reproduction | 1 | 2014 | 212 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 638 | 0.070 |
Why?
|
| Child | 1 | 2019 | 7745 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2026 | 1539 | 0.060 |
Why?
|
| Risk Factors | 2 | 2015 | 6271 | 0.060 |
Why?
|
| Ontario | 1 | 2026 | 32 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2023 | 46 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 480 | 0.050 |
Why?
|
| Recurrence | 1 | 2026 | 1264 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 146 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 7568 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 61 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2026 | 1752 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2023 | 331 | 0.040 |
Why?
|
| Adolescent | 1 | 2015 | 10137 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 173 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 187 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 453 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2026 | 992 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 238 | 0.040 |
Why?
|
| Autografts | 1 | 2020 | 38 | 0.040 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2020 | 4 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 201 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 341 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 74 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 78 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 326 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 218 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 214 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 3285 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 215 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 467 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1126 | 0.030 |
Why?
|
| PubMed | 1 | 2014 | 16 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2792 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2667 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 27 | 0.020 |
Why?
|
| Postmenopause | 1 | 2013 | 109 | 0.020 |
Why?
|
| Research | 1 | 2014 | 257 | 0.020 |
Why?
|
| Women's Health | 1 | 2013 | 120 | 0.020 |
Why?
|
| Vitamin D | 1 | 2013 | 286 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 3227 | 0.010 |
Why?
|